bioRxivBiochemistry
Control of topoisomerase II activity and chemotherapeutic inhibition by TCA cycle metabolites
J. H. Lee, E. P. Mosher, Y.-S. Lee, N. N. Bumpus, J. M. Berger
Abstract
Topoisomerase II (topo II) is essential for disentangling newly replicated chromosomes. DNA unlinking involves the physical passage of one DNA duplex through another and depends on the transient formation of double-strand DNA breaks, a step exploited by frontline chemotherapeutics to kill cancer cells. Although anti-topo II drugs are efficacious, they also elicit cytotoxic side effects in normal cells; insights into how topo II is regulated in different cellular contexts is essential to improve their targeted use. Using chemical fractionation and mass spectrometry, we have discovered that topo II is subject to metabolic control through the TCA cycle. We show that TCA metabolites stimulate topo II activity in vitro and that levels of TCA flux modulate cellular sensitivity to anti-topo II drugs in vivo. Our works reveals an unanticipated connection between the control of DNA topology and cellular metabolism, a finding with important ramifications for the clinical use of anti-topo II therapies.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms
S. X. Van Ravenstein, K. P. Mehta, … J. M. Dewar·bioRxiv·Oct 12, 2021
- Genome-scale genetic interactions position the Mitotic Exit Network as a major antagonist of transient Topoisomerase II deficiency.
Cristina Ramos-Pérez, Jessel Ayra‐Plasencia, … Félix Machín·G3 Genes Genomes GeneticsPeer-reviewed·Aug 24, 2017
- A multi-species toolkit of TOP2 hypercleavage mutants for studying topoisomerase II-mediated DNA damage
David Ontoso, Monika Mehta, … Scott Keeney·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 1, 2026
- Natural variation in a single amino acid underlies cellular responses to topoisomerase II poisons
Stefan Zdraljevic, Christine Strand, … Erik C. Andersen·PLoS GeneticsPeer-reviewed·Jul 12, 2017
- Systematic Generation of Mutations at Topoisomerase II Cleavage Sites Enables Cancer Adaptation to Doxorubicin Therapy
Valid Gahramanov, Anjana Edathil Kadangodan, … Michael Y. Sherman·bioRxiv·Aug 21, 2026
- Combinatorial Library Designing and Virtual Screening of Cryptolepine Derivatives against Topoisomerase IIA by Molecular Docking